{"filing":{"accession_number":"0001213900-26-086136","cik":"0001946563","ticker":"SXTPW","company_name":"60 DEGREES PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-05","primary_document":"ea0300977-8k_60degrees.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390026086136/ea0300977-8k_60degrees.htm"},"events":[{"id":25682,"run_id":23305,"accession_number":"0001213900-26-086136","anchor_item_number":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This 8-K discloses the results of 60 Degrees Pharmaceuticals' 2026 Annual Stockholders Meeting held on August 5, 2026, under Item 5.07. The filing reports voting outcomes for six proposals: election of five directors, approval of a 2022 Equity Incentive Plan amendment (800,000 additional shares), approval of a reverse stock split (1:5 to 1:10 ratio), ratification of RBSM LLP as independent auditor, approval of a management success fee for a change of control/sale of Arakoda, and adjournment authority. All six proposals were approved by majority vote. These results are material to investors as they affect board composition, equity dilution, capital structure (reverse split), auditor selection, and potential management incentives in a transaction.","company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTPW","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":26573,"accession_number":"0001213900-26-086136","item_number":null,"item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This 8-K discloses the results of 60 Degrees Pharmaceuticals' 2026 Annual Stockholders Meeting held on August 5, 2026, under Item 5.07. The filing reports voting outcomes for six proposals: election of five directors, approval of a 2022 Equity Incentive Plan amendment (800,000 additional shares), approval of a reverse stock split (1:5 to 1:10 ratio), ratification of RBSM LLP as independent auditor, approval of a management success fee for a change of control/sale of Arakoda, and adjournment authority. All six proposals were approved by majority vote. These results are material to investors as they affect board composition, equity dilution, capital structure (reverse split), auditor selection, and potential management incentives in a transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:22:27.104838+00:00","company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTPW","filing_date":"2026-08-06"}]}